Antiretroviral therapy reduces but does not normalize immune and vascular inflammatory markers in adults with chronic HIV infection in Kenya. (1st January 2021)
- Record Type:
- Journal Article
- Title:
- Antiretroviral therapy reduces but does not normalize immune and vascular inflammatory markers in adults with chronic HIV infection in Kenya. (1st January 2021)
- Main Title:
- Antiretroviral therapy reduces but does not normalize immune and vascular inflammatory markers in adults with chronic HIV infection in Kenya
- Authors:
- Temu, Tecla M.
Zifodya, Jerry S.
Polyak, Stephen J.
Wagoner, Jessica
Wanjalla, Celestine N.
Masyuko, Sarah
Nyabiage, Jerusha
Kinuthia, John
Bloomfield, Gerald S.
Page, Stephanie T.
Farquhar, Carey - Abstract:
- Abstract : Introduction: Markers of monocyte/macrophage activation and vascular inflammation are associated with HIV-related cardiovascular diseases (CVD) and mortality. We compared these markers among African people living with HIV (PLWH) and HIV-negative adults, and examined risk factors associated with elevated biomarkers (>75th percentile) in PLWH on antiretroviral therapy (ART). Design: Cross-sectional study. Methods: We measured serum concentrations of a gut integrity biomarker (intestinal-fatty acid binding protein), monocyte/macrophage activation biomarkers (soluble CD14 and CD163), and vascular inflammation biomarkers [soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vascular adhesion molecule 1 (sVCAM-1)]. We assessed the relationship of these inflammatory parameters with HIV, using logistic regression adjusting for traditional CVD risk factors. Results: Among the 541 participants, median age was 43 years and half were female. Among 275 PLWH, median CD4 + T-cell count and duration of ART use was 509 cells/μl and 8 years, respectively. PLWH had significantly higher prevalence of elevated inflammatory biomarkers compared with HIV-negative individuals even after adjustment for traditional CVD risk factors. Compared with individuals without HIV, the prevalence of elevated biomarkers was highest among persons with detectable viral load and CD4 + T-cell counts 200 cells/μl or less. In a subanalysis among PLWH, nadir CD4 + T-cell count 200 cells/μl or lessAbstract : Introduction: Markers of monocyte/macrophage activation and vascular inflammation are associated with HIV-related cardiovascular diseases (CVD) and mortality. We compared these markers among African people living with HIV (PLWH) and HIV-negative adults, and examined risk factors associated with elevated biomarkers (>75th percentile) in PLWH on antiretroviral therapy (ART). Design: Cross-sectional study. Methods: We measured serum concentrations of a gut integrity biomarker (intestinal-fatty acid binding protein), monocyte/macrophage activation biomarkers (soluble CD14 and CD163), and vascular inflammation biomarkers [soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vascular adhesion molecule 1 (sVCAM-1)]. We assessed the relationship of these inflammatory parameters with HIV, using logistic regression adjusting for traditional CVD risk factors. Results: Among the 541 participants, median age was 43 years and half were female. Among 275 PLWH, median CD4 + T-cell count and duration of ART use was 509 cells/μl and 8 years, respectively. PLWH had significantly higher prevalence of elevated inflammatory biomarkers compared with HIV-negative individuals even after adjustment for traditional CVD risk factors. Compared with individuals without HIV, the prevalence of elevated biomarkers was highest among persons with detectable viral load and CD4 + T-cell counts 200 cells/μl or less. In a subanalysis among PLWH, nadir CD4 + T-cell count 200 cells/μl or less was associated with elevated soluble CD14 (sCD14); dyslipidemia with elevated sCD14, sICAM-1, and sVCAM-1; and overweight/obesity with reduced sCD14. Longer ART exposure (>4 years) was associated with reduced sVCAM-1 and sICAM-1. Conclusion: HIV and not traditional CVD risk factors is a primary contributor of monocyte/macrophage activation and inflammation despite ART. Anti-inflammatory therapies in addition to ART may be necessary to reduce these immune dysregulations and improve health outcomes of African PLWH. Abstract : Supplemental Digital Content is available in the text … (more)
- Is Part Of:
- AIDS. Volume 35:Number 1(2021)
- Journal:
- AIDS
- Issue:
- Volume 35:Number 1(2021)
- Issue Display:
- Volume 35, Issue 1 (2021)
- Year:
- 2021
- Volume:
- 35
- Issue:
- 1
- Issue Sort Value:
- 2021-0035-0001-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-01-01
- Subjects:
- Africa -- cardiovascular diseases -- HIV -- inflammation -- monocyte activation
AIDS (Disease) -- Periodicals
Acquired Immunodeficiency Syndrome
AIDS (Disease)
Periodicals
Periodicals
616.9792005 - Journal URLs:
- http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&PAGE=toc&D=ovft&AN=00002030-000000000-00000 ↗
http://journals.lww.com/aidsonline/pages/default.aspx?desktopMode=true ↗
http://journals.lww.com/pages/default.aspx ↗ - DOI:
- 10.1097/QAD.0000000000002729 ↗
- Languages:
- English
- ISSNs:
- 0269-9370
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0773.083000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 21943.xml